Confo Therapeutics
Thomas Fontaine has extensive experience in scientific research and development, currently serving as an Associate Scientist at Confo Therapeutics since December 2016. Prior roles include Associate Scientist at UCB and various positions, including Research Associate and Senior Research Associate, which involved cell culture process development. Early career experience includes internships at MedImmune, focusing on the therapeutic potential of GPCRs in diabetes and obesity, and at Lehning Laboratories, where Thomas engaged in manufacturing, quality assurance, and quality control processes. Academic credentials include a Master's degree in Biotechnology from ENSTBB Bordeaux INP, alongside a Baccalaureate diploma with first class honours in the Scientific category from Georges-de-la-Tour.
This person is not in any offices
Confo Therapeutics
1 followers
Confo Therapeutics is an emerging drug discovery company built around a disruptive technology to enable the discovery of GPCR agonists. The CONFO® technology uses single domain antibodies to lock inherently unstable GPCRs in the druggable conformation and uses this stabilized complex as a superior starting point for GPCR drug discovery.